Glucagon-like receptor agonists (GLP-1 RAs) have been extensively studied in cardiovascular outcome trials (CVOTs) of patients with type 2 diabetes (T2DM) and established or high risks of atherosclerotic cardiovascular disease (ASCVD) either with or without CKD [101]. The gene discussed is GCG; the disease is chronic kidney disease.